The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
暂无分享,去创建一个
T. Nakagawa | S. Yano | Kunio Matsumoto | S. Takeuchi | Tadaaki Yamada | Takako Sano | S. Nanjo | Daisuke Ishikawa | Takahiro J. Nakamura